U.S. biofilms treatment market is projected to register a CAGR of 8.0% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
U.S. Biofilms Treatment Market, By Wound Type (Traumatic and Surgical Wound, Diabetic Foot Ulcers, Open Wound, Pressure Ulcers, Venous Leg Ulcer, Chronic Sinusitis, Burns, Dental Plaque, Others), Methods (Prevention, Killing, Debridement), Product (Gauzes and Dressings, Wipes, Pads and Lavage Solutions, Gels, Ointment and Spray, Grafts and Matrices, Debridement Equipment, Others), Treatment (Biofilm Disruptors, Antimicrobial Treatments, Antibiotic Medication, Photo Inactivation, Others), Route of Administration (Topical, Oral, Others), End User (Hospitals, Wound Care Centers, Clinics, Home Healthcare, Ambulatory Surgical Centers, Others), Distribution Channel (Direct Tender, Pharmacies, Retail Sales, Others) Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of U.S. biofilms treatment market are:

- Rising prevalence of chronic, surgical and traumatic wounds
- Favourable reimbursement for biofilm treatment products and procedures
Market Players:

The key market players for U.S. biofilms treatment market are listed below:

- Smith+Nephew
- ConvaTec Inc. (A Subsidiary of ConvaTec Group PLC)
- Coloplast Group
- Organogenesis Inc.
- B. Braun Melsungen AG (A Subsidiary of B. Braun Holding GmbH & Co. KG)
- Zimmer Biomet
- PulseCare Medical
- Integra LifeSciences Corporation
- HARTMANN USA, Inc. (A Subsidiary of Hartmann AG)
- 3M
- Sanara MedTech Inc.
- Misonix
- Kerecis
- Next Science Limited
- MiMedx
- Molnlycke Health Care AB
- Medline Industries, Inc.